Novavax Begins Phase 1/2 Study for Its Combination COVID …

NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

https://www.contagionlive.com/view/novavax-begins-phase-1-2-study-for-its-combination-covid-19-and-influenza-vaccine